ATRACURIUM BESYLATE PRESERVATIVE FREE Drug Patent Profile

When do Atracurium Besylate Preservative Free patents expire, and what generic alternatives are available?

Atracurium Besylate Preservative Free is a drug marketed by Baxter Hlthcare, Baxter Hlthcare Corp, Eugia Pharma, Hikma, Hospira, Hospira Inc, Meitheal, Pharmobedient, and Watson Labs Inc. and is included in eleven NDAs.

The generic ingredient in ATRACURIUM BESYLATE PRESERVATIVE FREE is atracurium besylate. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the atracurium besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Atracurium Besylate Preservative Free

A generic version of ATRACURIUM BESYLATE PRESERVATIVE FREE was approved as atracurium besylate by HIKMA on July 18^th, 1997.

Summary for ATRACURIUM BESYLATE PRESERVATIVE FREE

US Patents:	0
Applicants:	9
NDAs:	11
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	105
Patent Applications:	1,119
DailyMed Link:	ATRACURIUM BESYLATE PRESERVATIVE FREE at DailyMed

Pharmacology for ATRACURIUM BESYLATE PRESERVATIVE FREE

Drug Class	Nondepolarizing Neuromuscular Blocker
Physiological Effect	Neuromuscular Nondepolarizing Blockade

US Patents and Regulatory Information for ATRACURIUM BESYLATE PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	074825-001	Sep 30, 1997		DISCN	No	No
Hospira	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	074741-001	Mar 28, 1997		DISCN	No	No
Hikma	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	074900-001	Jul 18, 1997	AP	RX	No	Yes
Hospira Inc	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	090782-001	Oct 18, 2012	AP	RX	No	No
Baxter Hlthcare Corp	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	074768-001	Jan 23, 1997		DISCN	No	No
Eugia Pharma	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	206010-001	Apr 8, 2015		DISCN	No	No
Hospira	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	074639-001	Mar 25, 1997		DISCN	No	No

ATRACURIUM BESYLATE PRESERVATIVE FREE Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for ATRACURIUM BESYLATE PRESERVATIVE FREE?

The global market for atracurium besylate preservative-free (PF) is driven primarily by the increasing adoption of neuromuscular blocking agents (NMBAs) in surgical procedures. The demand for PF formulations stems from concerns about preservative-related allergic reactions and the shift toward more biocompatible anesthetic drugs.

Key Market Drivers

1. Rising Surgical Volume: The expansion of outpatient and inpatient surgical procedures, notably under anesthesia that requires neuromuscular blockade.
2. Preference for Preservative-Free Formulations: Concerns over preservative-related adverse effects (e.g., allergic reactions and local tissue toxicity) encourage hospitals to select PF options.
3. Growth in Anesthesiology Procedures: Advanced surgical techniques, including minimally invasive surgeries, augment the need for reliable neuromuscular blockers.
4. Regulatory Environment: Increasing approval of PF formulations by agencies such as FDA and EMA enhances market access for newer drugs.
5. Hospital Accreditation and Patient Safety Policies: Emphasis on reducing drug-related side effects fosters uptake of PF drugs.

Market Restraints

• Pricing and Reimbursement Challenges: PF drugs tend to be priced higher than preservative-containing counterparts, affecting adoption in cost-sensitive markets.
• Limited Market Penetration of Certain Formulations: Established brands with preservative-based options hold significant market share, delaying PF variant adoption.
• Production Complexities: Manufacturing preservative-free formulations involves more stringent processes, which can increase costs.

Competitive Landscape

Major pharmaceutical companies such as Fresenius Kabi, Hospira (a Pfizer company), and Teva Pharmaceuticals develop and market atracurium besylate PF formulations. These firms benefit from patent expirations and generic competition, making pricing strategies a critical competitive factor.

Regional Market Outlook

• North America: Dominates the global market due to high surgical rates, advanced healthcare infrastructure, and favorable regulatory environment.
• Europe: Strong growth driven by hospital policies favoring PF drugs, with regulatory frameworks supporting approval processes.
• Asia-Pacific: Fastest growth rate, fueled by increasing healthcare spending, expanding surgical procedures, and rising awareness of drug safety.

What Is the Financial Trajectory for ATRACURIUM BESYLATE PRESERVATIVE FREE?

Financial prospects for atracurium besylate PF depend on market penetration, pricing strategies, and regulatory approvals.

Revenue Estimates and Growth Projections

• Market Size (2022): The global neuromuscular blocking agent market was valued at approximately USD 800 million.
• Growth Rate: Compound annual growth rate (CAGR) from 2022 to 2030 is projected at 4.5%–6%, driven by the factors outlined above.
• Market Share of Atracurium PF: Estimated at roughly 20% of the neuromuscular blocker market, with potential to increase as PF formulations gain acceptance.

Pricing Dynamics

• Average Price per Vial: Estimated USD 15–20 for preservative-free formulations versus USD 12–15 for preservative-containing equivalents.
• Cost Impact: Higher manufacturing costs for PF drugs can limit price competitiveness unless offset by volume growth.

Profitability Considerations

• Margins: Generally lower for generic PF formulations due to price competition.
• Market Entry Costs: Significant initial investments in manufacturing infrastructure and regulatory compliance.
• Growth Opportunities: Expansion into emerging markets and hospital procurement contracts.

Regulatory and Patent Considerations

• Patent Expirations: Several formulations of atracurium besylate face patent cliffs in the coming years, opening opportunities for generics.
• Regulatory Approvals: Streamlined approval pathways in regions like the US (via FDA) and Europe (via EMA) bolster market potential.

Key Takeaways

• The market for atracurium besylate preservative-free is expanding, driven by surgical demand and safety concerns.
• North America and Europe lead adoption; Asia-Pacific offers significant growth potential.
• Pricing pressures and manufacturing complexities challenge profitability but can be mitigated by increased volume and strategic regional expansion.
• Patent expirations and regulatory approvals influence future market entry and product lifecycle.

FAQs

1. What factors influence the adoption of preservative-free atracurium besylate?
   Hospital safety protocols, regulatory approvals, surgical volume, and cost considerations.

2. How does the price of preservative-free formulations compare to preserved ones?
   PF formulations typically cost USD 3–5 more per vial due to manufacturing complexity.

3. Which regions are expected to see the highest growth in this market?
   Asia-Pacific, driven by rising healthcare investment and surgical procedures.

4. What is the impact of patent expirations on the market?
   They open opportunities for generics, increasing competition and potentially lowering prices.

5. Are there emerging alternatives to atracurium besylate PF?
   Yes, other neuromuscular blockers like rocuronium or vecuronium, but atracurium remains preferred for specific indications.

References

1. MarketWatch. "Neuromuscular blocking agents market size." 2022.
2. Grand View Research. "Global anesthetic market analysis." 2021.
3. FDA. "Guidance for Industry – Preservative-Free Formulations." 2020.
4. Evaluate Pharma. "Biopharmaceutical forecasts." 2022.
5. IQVIA. "Global drug spend analysis." 2022.